If you'd like to claim this profile on behalf of your company, please Contact Us.
 

Latest news ...

Some of our recent news articles.

 
09
December
2020
09th December 2020
 

Horizon Therapeutics and Halozyme Therapeutics enter license Agreement for ENHANZE® Technology

DUBLIN and SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Horizon Therapeutics plc (Nasdaq:  HZNP) and Halozyme Therapeutics, Inc. (Nasdaq:  HALO) today announced a global collaboration and license agreement that gives Horizon exclusive access to Halozyme's ENHANZE® drug delivery technology for subcutaneous (SC) formulation of medicines targeting IGF-1R.  Horizon intends to use ENHANZE® to develop a SC formulation of TEPEZZA (teprotumumab-trbw), indicated for the treatment of Thyroid Eye Disease, a serious, progressive and vision-threatening rare autoimmune disease,1 potentially shortening drug administration time, reducing healthcare practitioner time and offering additional flexibility and convenience for patients.


Under the terms of the agreement, Horizon will make an upfront payment of $30 million to Halozyme and is obligated to make potential future payments of up to $160 million in the aggregate, subject to achievement of specified development, regulatory and sales-based milestones.  Halozyme will also be entitled to receive mid-single digit royalties on sales of commercialized medicines using the ENHANZE® technology.


"Our goal with all of our medicines is to optimize the patient experience," said Tim Walbert, chairman, president and chief executive officer, Horizon.  "As we continue to explore subcutaneous administration for TEPEZZA to provide greater flexibility for patients and physicians, access to the ENHANZE® technology, which has been deployed successfully in multiple biologics, represents an important step in our development efforts."

 
Read the full story »
 
 
 
 
 
 
 
 
 

About Us

SURIMS is the new name for Actex Pharma Services which was a consultancy established in 2003, supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own supplier on-boarding and supplier management activities. Further information on our software services please contact Tel: +353 87 294 0436 or email info@surims.com

 
 
 

Get in Touch

The Pharmaceutical Services Directory
info@surims.com

 
 
 

© 2021 Surims Ltd | All Rights Reserved.